Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Abbott Laboratories

ABT Healthcare Unknown Updated July 31, 2026
$105.72
52W $81.97 – $137.49
55/100
$184.11B
34.0
0.61
AI Committee Verdict
Watch
Conviction: Moderate · 71% agreement · 7 analysts
+0.8%
-0.2%
3.95:1
Moderate

Is ABT Bullish or Bearish?

Mixed. Innellis AI committee rates Abbott Laboratories (ABT) Watch with a composite score of 55/100 , based on 7 analysts with 71% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +4.57 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -15.43 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Some positive signals exist — news sentiment is positive (+0.40 across 63 articles, 14d) — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock — Risk
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.40 across 63 articles, 14d) — News
Bear Case
  • P/E of 33.7 is moderate-to-rich — Value
  • Price-to-book of 4.2x prices in significant intangible value — Value
  • EPS declining -61.2% YoY despite any revenue growth — Growth
  • Bollinger bandwidth of 22.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
55/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 53%
of 93 Healthcare peers
Value Analyst neutral
47 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 33.7 is moderate-to-rich
Growth Analyst neutral
48 / 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -61.2% YoY despite any revenue growth
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst bullish
62 / 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock
− Bollinger bandwidth of 22.8% signals elevated volatility
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
70 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 63 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 54.2 to 55.4.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • News Analyst: +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Risk Analyst: stance neutral->bullish; score 58->62 (+4); +1 bearish signal(s).
  • Technical Analyst: score 48->58 (+10).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
67.6
Neutral
MACD Histogram
0.713
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$105.50
Resistance
$106.60
Bollinger %B
0.79
Inside Bands
Price vs Moving Averages
EMA 9
$103.96 Above
EMA 21
$100.04 Above
EMA 50
$96.44 Above
EMA 200
$105.20 Above

Fundamental Analysis

Valuation
64
Growth
59
Profitability
0
Financial Health
71
Cash Flow
37
Valuation
P/E Ratio 34.0×
P/B Ratio 3.60×
PEG Ratio -0.55
Dividend Yield 0.02%
52W High $137.49
52W Low $81.97
Quality & Growth
ROE 12.5%
ROA 7.5%
Gross Margin 56.8%
Operating Margin 17.0%
Revenue Growth YoY
Debt / Equity 0.64
AI Fundamental Assessment
P/E ratio of 34.0 (rich relative to a 15-40x range); Price-to-book of 3.6x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.1%; Gross margin of 0.6%; Current ratio of 1.38 (tight short-term liquidity); Debt-to-equity of 0.64; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (5.00); Most recent quarter beat estimates by 1.4%; EPS growth accelerating (-23.3% -> +13.9% QoQ); Average YoY EPS growth of 4.0%; Analyst estimates falling over recent quarters
Get the Full ABT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore ABT Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime